More Tuesday Analyst Upgrades and Downgrades: With Fed Rate Hike Coming, Analysts Target GoodRx, Mosaic, Nektar Therapeutics and More

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
More Tuesday Analyst Upgrades and Downgrades: With Fed Rate Hike Coming, Analysts Target GoodRx, Mosaic, Nektar Therapeutics and More

© pinstock / Getty Images

Markets edged higher to start off Tuesday, as West Texas Intermediate crude slid below the $100 mark. The rebound in markets also saw gold and silver prices decline as investors seem to be gaining confidence, at least for now.

Still, inflation has hit record levels and consumers are feeling the sting. The most recent consumer price index reading from last week rose by 7.9% year over year for the month of February, hitting a 40-year high. Consumers also have been hit by rising gasoline prices due to the Russia-Ukraine conflict’s supply shock.

Later this week, economists anticipate the Federal Reserve will raise the federal funds rate in an effort to counter inflation, but it is unclear if this will have any immediate effect. Many believe that the rate hike is already priced in, given that markets are in correction territory, with the Nasdaq in bear market stance. The recent decline may be due in part to the prospect of rising rates, but there are plenty of overriding headwinds.

24/7 Wall St. is reviewing some big analyst calls seen on Tuesday. We have included the latest call on each stock, as well as a recent trading history and the consensus targets among analysts. Note that analyst calls seen earlier in the day were on Bumble, Chevron, Hormel, Lululemon, Nike, Target, Unilever, Zoom Video and many more.

[nativounit]

Ascendis Pharma A/S (NASDAQ: ASND): BofA Securities upgraded the stock to Buy from Neutral and raised the $148 price target to $161. The 52-week trading range is $96.97 to $178.71, and shares were trading near $106 on Tuesday.

Coupa Software Inc. (NASDAQ: COUP): Oppenheimer downgraded the shares to Perform from Outperform. The stock traded near $66 on Tuesday. The 52-week range is $64.79 to $286.22.

Evolv Technologies Holdings Inc. (NASDAQ: EVLV): Stifel lowered its Buy rating to Hold and slashed the price target to $2 from $10. Shares were trading near $2 on Tuesday. The 52-week range is $1.86 to $12.90.

GoodRx Holdings Inc. (NASDAQ: GDRX | GDRX Price Prediction): Robert Baird’s upgrade to Outperform from Neutral came with a $17 price target. Shares were trading near $14 on Tuesday. The 52-week range is $13.44 to $48.05.

Heartland Express Inc. (NASDAQ: HTLD): Morgan Stanley upgraded it from Underweight to Equal Weight with a $16 price target. Shares were trading near $15. The 52-week range is $13.85 to $20.07.

LiveRamp Holdings Inc. (NYSE: RAMP): The Market Perform rating at BMO Capital Markets was lifted to Outperform with a $48 price target. Shares were trading near $35 on Tuesday. The 52-week range is $33.42 to $58.74.

Mosaic Co. (NYSE: MOS): Goldman Sachs upgraded the stock to Buy from Neutral and has an $83 price target. The 52-week trading range is $28.26 to $64.71, and shares were trading near $57 apiece on Tuesday.

Nektar Therapeutics (NASDAQ: NKTR): Cowen downgraded the shares to Market Perform from Outperform. Mizuho’s downgrade to Neutral from Buy included a price target cut to $8 from $35. The stock was trading near $4 on Tuesday, and the 52-week range is $3.88 to $23.50.

Prelude Therapeutics Inc. (NASDAQ: PRLD): The BofA Securities downgrade was to Neutral from Buy, and the firm cut the $50 price target to $10. The 52-week trading range is $6.93 to $62.75, and shares were trading near $7 on Tuesday.

W.W. Grainger Inc. (NYSE: GWW): Atlantic Equities upgraded it from Neutral to Overweight with a $580 price target. Shares were trading near $496. The 52-week range is $387.60 to $527.06.

[recirclink id=1066985]
Most companies detest higher interest rates, as they increase borrowing costs and the overall cost of doing business. But five Warren Buffett picks are likely to be beneficiaries of higher rates, and they pay very solid and dependable dividends to shareholders too.
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618